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University Department of Clinical Oncology, Regional Radiotherapy Centre, Newcastle General Hospital, Newcastle upon
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The synthesis of CB3717, N10-propargyl-5,8 dideazafolic
acid, and its introduction into clinical practice represented a
new development in antifolate cancer chemotherapy (Calvert
et al., 1987). CB3717 is a tight binding inhibitor of thymidy-
late synthetase (TS) and in human tumour cell lines over-
came methotrexate resistance regardless of whether the
resistance was due to an elevated level of dihydrofolate
reductase or reduced membrane transport of methotrexate
(Jones et al., 1981; Diddens et al., 1983). In early clinical
studies dose limiting toxicity was renal, responses occurred at
doses >200mgm-2 and most patients developed reversible
biochemical abnormalities of liver function associated with
malaise (Calvert et al., 1986). Phase I evaluation of CB3717
revealed antitumour activity in human breast and ovary
cancer. Two of 4 patients with colon cancer had minor
responses (Calvert et al., 1986). In phase II evaluation there
was significant antitumour activity in hepatoma (Bassendine
et al., 1987), and to a lesser extent in heavily pretreated
patients with advanced breast cancer (Cantwell et al., 1988).
5-Fluorouracil is the single most active agent in colorectal
adenocarcinoma (Moertel, 1978). The metabolism of 5-
fluorouracil is complex and the mechanisms of its cytotoxicity
are mediated via both RNA and through TS inhibition
(Grem et al., 1987). Thus we considered it of potential value
to combine 5-fluorouracil with a specific inhibitor of TS
(CB3717) to treat colorectal adenocarcinoma, since resistance
to TS mediated actions of 5-fluorouracil may be overcome
by CB3717.
Twelve chemotherapy-naive patients with colorectal ade-
nocarcinoma were treated with CB3717 300mgm-2 i.v. over
1 h and courses were repeated every 3 weeks. 5-Fluorouracil
(1 g) was given i.v. with CB3717 and 1 g was taken orally
once each week between i.v. therapies. Median age of
patients was 55 years, range 35-70 years. Median perfor-
mance status was 1, range 0-2 (WHO, 1979). Dominant sites
of metastatic disease were liver in 8, pulmonary in 2 and
recurrent intraabdominal disease in 2 patients. Some patients
had more than one metastatic site.
Patients received a median of 3 courses of combined
therapy (range 2-6 courses) and 3 patients had a maximum
of 6 courses each. Full blood counts, serum bilirubin,
alkaline phosphatase (AP), aspartate transaminase (AST),
creatinine, urea, sodium, chloride, and potassium were esti-
mated before each course. Similarly 24h creatinine clear-
ances were estimated usually before each course. Clinical
examinations and periodic chest X-rays, isotopic and sono-
graphic hepatic scans, and computed tomograms were per-
formed to assess response.
There were no objective responses. Confidence limits for
this observation were 0%-26.4%, 95% confidence level. Two
patients, both with liver metastases, had some improvement
in symptoms and biochemical estimates of liver dysfunction,
but neither had any significant tumour regression on serial
hepatic scans.
Eight patients had moderate to severe malaise after most
courses. Ten had nausea, usually mild and lasting at most
for 48h after CB3717 courses. Two of these patients had
associated vomiting. Five patients had painful conjunctivitis
after most of their treatment courses and 2 of these patients
also had stomatitis.
Myelosuppression was not detected. No patient had
abnormally elevated serial serum creatinine levels, but 8
patients had falls in 24h creatinine clearances reaching a
maximum in one patient of 45% fall from baseline value.
Ten patients had AST elevation during therapy reaching a
maximum of WHO grade 3 in 4 patients. Six patients had
WHO grade 1 elevation of AP. The interpretation of these
abnormalities is difficult as the majority of patients had liver
metastases, but biochemical abnormalities due to CB3717 are
well documented (Calvert et al., 1986).
Our results and those of Harding et al. (1988) in patients
with colorectal cancer treated with CB3717 monotherapy
suggest that specific TS inhibition is unlikely to have clinical
benefit in colorectal cancer. CB3717 doses of 300mgm-2
every 3 weeks in other studies were adequate to induce
tumour regression in sensitive tumour types (Bassendine et
al., 1987; Cantwell et al., 1988). Our inability to demonstrate
increased antitumour activity by combining CB3717 with 5-
fluorouracil further suggests that TS inhibition may not be
an important mechanism for the in vivo antitumour activity
of 5-fluorouracil.
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